ProKidney drops $25.5M on North Carolina manufacturing site for cell therapy prospect

ProKidney is the latest company to join the bustling North Carolina manufacturing scene with a $25.5 million initial investment. The company has purchased 22 acres of land and a 210,000-square-foot facility in Greensboro, North Carolina, and will begin preparing it to produce its lead drug. The renal autologous cell therapy, known as REACT, is currently in phase 3 development to treat diabetic chronic kidney disease (CKD).